Clinical trials: Celiac Disease
Celiac Disease
AMG 714 Expanded Access Program
Expanded access requests for AMG 714 may be considered for adult patients with biopsy proven Refractory Celiac Disease Type II who have failed all available treatment options and do not have EATL.
- Trial name
- NCT03439475
- Testing
- AMG 714
- Sponsor
- Amgen
Celiac Disease
Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease
This study was conducted to evaluate the efficacy of multiple doses of larazotide acetate in preventing intestinal permeability changes induced by a 6- week gluten challenge in subjects with celiac disease.
- Trial name
- NCT00492960
- Testing
- larazotide acetate, 900 mg gluten
- Where
- 23 sites in United States, Canada
- Volunteers
- 171 people
- Sponsor
- 9 Meters Biopharma, Inc.
Celiac Disease
Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease
A phase 2a study to evaluate the safety and efficacy of ALV003 to treat celiac disease.
- Trial name
- NCT01255696
- Testing
- ALV003
- Where
- 3 sites in Finland
- Volunteers
- 61 people
- Sponsor
- Alvine Pharmaceuticals Inc.
Celiac Disease
Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease
A randomized, double-blind, placebo-controlled, dose titration trial, stratified by Human Leukocyte Antigen (HLA)-DQ2.5 genotype in subjects with celiac disease.
- Trial name
- NCT02528799
- Testing
- Nexvax2
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 38 people
- Sponsor
- ImmusanT, Inc.
Irritable Bowel Syndrome, Crohn Disease
Effect of UGIR in Adults With Compromised Gut Function and Malabsorption
This study assessed the effect of a nutrition support product on quality of life in adults with compromised gut function and malabsorption.
- Conditions
- Irritable Bowel Syndrome, Crohn Disease, Ulcerative Colitis, Celiac Disease
- Trial name
- NCT03011593
- Testing
- Nutrition Support Product
- Volunteers
- 18 people
- Sponsor
- Metagenics, Inc.
Coeliac Disease, Celiac Disease
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a…
- Trial name
- NCT06557772
- Testing
- Amlitelimab, SIGE, Gluten-free product (GFP)
- Where
- 118 sites in United States, Argentina and 19 more
- Volunteers
- 229 people
- Sponsor
- Sanofi
Celiac Disease, Coeliac Disease
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole
This is a 3-part first time into human study (FTIH) study for GSK3915393. Parts A and B of the study will evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending and repeat oral doses of GSK3915393 in…
- Trial name
- NCT04604795
- Testing
- GSK3915393 Capsules, GSK3915393 Solution for Infusion, Itraconazole
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Autoimmune Diseases, Ulcerative Colitis
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation.
- Conditions
- Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma
- Trial name
- NCT06587828
- Testing
- Companion blood samples with procedure
- Where
- 11 sites in United States
- Volunteers
- 238 people
- Sponsor
- TScan Therapeutics, Inc.
Celiac Disease
A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease
To assess the efficacy and safety of AGY vs placebo when administered to individuals age 10 to 65 years with medically proven CD and on a gluten free diet
- Trial name
- AGY-010 (NCT03707730)
- Testing
- AGY
- Where
- 2 sites in Canada
- Volunteers
- 161 people
- Sponsor
- Igy Inc.
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Celiac Disease
A Phase II Study of CCX282-B in Patients With Celiac Disease
The purpose of this study is to determine whether CCX282-B is effective in mitigating the effects of gluten ingestion in patients with celiac disease
- Trial name
- NCT00540657
- Testing
- CCX282-B
- Where
- Finland
- Volunteers
- 90 people
- Sponsor
- Amgen
Celiac Disease
Assessment of KAN-101 in Celiac Disease (ACeD)
A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2.
- Trial name
- NCT04248855
- Testing
- KAN-101
- Where
- 13 sites in United States
- Volunteers
- 41 people
- Sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Celiac Disease, Non-celiac Gluten Sensitivity
Probiotic BL NCC 2705 and Gluten Sensitivity
The aim of the study is to confirm/prove safety of the probiotic and production of serpin in humans.
- Trial name
- NCT03775499
- Testing
- Intervention 1 : BL NCC 2705 + Maltodextrin, Intervention 1 : Maltodextrin, Intervention 2 : BL NCC 2705 + Maltodextrin
- Where
- Netherlands
- Volunteers
- 38 people
- Sponsor
- Société des Produits Nestlé (SPN)
Celiac Disease
Safety and Efficacy of ALV003 for the Treatment of Celiac Disease
A phase 2a study to evaluate the safety and efficacy of ALV003 to treat celiac disease.
- Trial name
- NCT00959114
- Testing
- ALV003
- Where
- Finland
- Volunteers
- 74 people
- Sponsor
- Alvine Pharmaceuticals Inc.
Celiac Disease
Safety Study of Larazotide Acetate to Treat Celiac Disease.
To demonstrate the safety, pharmacokinetics and efficacy of larazotide acetate in patients with controlled celiac disease on a gluten-free diet following a gluten challenge.
- Trial name
- NCT00386165
- Testing
- larazotide acetate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- 9 Meters Biopharma, Inc.
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Celiac Disease
Oral AGY for Celiac Disease
Celiac disease (CD) is an autoimmune disease of the small intestine caused by the consumption of gluten proteins from widely used food sources such as wheat, rye, and barley.
- Trial name
- NCT01765647
- Testing
- AGY
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Igy Inc.
Celiac Disease
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms
To assess the efficacy and safety of larazotide acetate versus placebo for the relief of persistent symptoms in adult celiac disease patients.
- Trial name
- NCT03569007
- Testing
- Larazotide
- Where
- 160 sites in United States
- Volunteers
- 307 people
- Sponsor
- 9 Meters Biopharma, Inc.
Celiac Disease
Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge
The primary purpose of this study is to characterize changes in gluten-specific T cells and pathology in the small intestine with specific focus on biomarkers likely to change with therapeutic celiac disease (CeD) treatment.
- Trial name
- NCT03409796
- Testing
- Gluten
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Takeda
Celiac Disease
A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)
This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).
- Trial name
- NCT05574010
- Testing
- Cohort 1 in Part A, Cohort 2 in Part A, Group 2 in Part B and Part C
- Where
- 36 sites in United States, Australia and 1 more
- Volunteers
- 128 people
- Sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA